PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
1967149-1	1990	We have previously shown that 131I-labeled monoclonal antibodies against the Thy1.1 differentiation antigen can induce the regression of Thy1.1 antigen-positive (Thy1.1+) AKR/J SL2 T cell lymphoma nodules in AKR/Cum (Thy1.2+) mice.	Iodine-131	30-34	thymus cell antigen 1, theta	Mus musculus	77-83	
1967149-1	1990	We have previously shown that 131I-labeled monoclonal antibodies against the Thy1.1 differentiation antigen can induce the regression of Thy1.1 antigen-positive (Thy1.1+) AKR/J SL2 T cell lymphoma nodules in AKR/Cum (Thy1.2+) mice.	Iodine-131	30-34	thymus cell antigen 1, theta	Mus musculus	137-143	
1967149-1	1990	We have previously shown that 131I-labeled monoclonal antibodies against the Thy1.1 differentiation antigen can induce the regression of Thy1.1 antigen-positive (Thy1.1+) AKR/J SL2 T cell lymphoma nodules in AKR/Cum (Thy1.2+) mice.	Iodine-131	30-34	thymus cell antigen 1, theta	Mus musculus	137-143	
1967149-1	1990	We have previously shown that 131I-labeled monoclonal antibodies against the Thy1.1 differentiation antigen can induce the regression of Thy1.1 antigen-positive (Thy1.1+) AKR/J SL2 T cell lymphoma nodules in AKR/Cum (Thy1.2+) mice.	Iodine-131	30-34	thymus cell antigen 1, theta	Mus musculus	217-223	
1967149-2	1990	In this study, we examined the ability of 131I-labeled anti-Thy1.1 antibodies to eliminate tumor nodules containing variant lymphoma cells that do not express the Thy1.1 antigen (Thy1.1-).	Iodine-131	42-46	thymus cell antigen 1, theta	Mus musculus	60-66	
1967149-4	1990	One week later, when an established tumor nodule was present, mice were treated with 1,500-1,700 microCi of 131I-labeled anti-Thy1.1 antibody.	Iodine-131	108-112	thymus cell antigen 1, theta	Mus musculus	126-132	
1967149-6	1990	In contrast, no complete regressions were observed in mice with only antigen-negative tumor cells treated with 131I-labeled anti-Thy1.1 antibody or in mice inoculated with antigen-positive tumor and treated with an 131I-labeled control antibody.	Iodine-131	111-115	thymus cell antigen 1, theta	Mus musculus	129-135	
3779642-1	1986	We have shown previously that 131I-labeled antibodies against the Thy-1.1 differentiation antigen can cure AKR/Cum (Thy-1.2+) mice bearing AKR/J (Thy-1.1+) SL2 T-cell lymphoma.	Iodine-131	30-34	thymus cell antigen 1, theta	Mus musculus	66-73	
3501420-2	1987	In our studies of the 131I-labeled anti-Thy 1.1 antibody treatment of murine lymphoma we have used cell binding assays with a combination of Lineweaver-Burk analysis to determine immunoreactivity and Scatchard analysis to determine antibody avidity.	Iodine-131	22-26	thymus cell antigen 1, theta	Mus musculus	40-47	
3501420-4	1987	For 131I-labeled anti-Thy 1.1 antibody, avidity was a much more sensitive indicator of iodination damage and predictor of in vivo behavior than was immunoreactivity, while for other antibodies immunoreactivity has been a better indicator of labeling damage.	Iodine-131	4-8	thymus cell antigen 1, theta	Mus musculus	22-29	
3779642-1	1986	We have shown previously that 131I-labeled antibodies against the Thy-1.1 differentiation antigen can cure AKR/Cum (Thy-1.2+) mice bearing AKR/J (Thy-1.1+) SL2 T-cell lymphoma.	Iodine-131	30-34	thymus cell antigen 1, theta	Mus musculus	116-123	
3779642-1	1986	We have shown previously that 131I-labeled antibodies against the Thy-1.1 differentiation antigen can cure AKR/Cum (Thy-1.2+) mice bearing AKR/J (Thy-1.1+) SL2 T-cell lymphoma.	Iodine-131	30-34	thymus cell antigen 1, theta	Mus musculus	146-153	
3779642-2	1986	In the present study we have extended these studies to the therapy of SL2 lymphoma in AKR/J mice, where 131I-anti-labeled Thy-1.1 antibodies react with both tumor and normal T-lymphocytes.	Iodine-131	104-108	thymus cell antigen 1, theta	Mus musculus	122-129	
3779642-3	1986	A single 25-micrograms bolus of 131I-labeled anti-Thy-1.1 antibody was rapidly cleared from serum by binding to spleen cells (t1/2 less than 3 h) and only low concentrations (less than 2% injected dose/g) were present in tumor 24 h after infusion.	Iodine-131	32-36	thymus cell antigen 1, theta	Mus musculus	50-57	
3779642-7	1986	Therapy of AKR/J mice bearing established s.c. lymphoma nodules with 1,500 mu Ci of 131I-anti-Thy-1.1 antibody given in this latter regimen resulted in complete regression of the nodule in 70% of animals and had a greater antitumor effect (27% complete regression, P less than 0.001) than 750 mu Ci of 131I-labeled irrelevant antibody, a dose that would deliver equivalent radiation to normal organs (liver, kidney, and lung).	Iodine-131	84-88	thymus cell antigen 1, theta	Mus musculus	94-101	
3779642-7	1986	Therapy of AKR/J mice bearing established s.c. lymphoma nodules with 1,500 mu Ci of 131I-anti-Thy-1.1 antibody given in this latter regimen resulted in complete regression of the nodule in 70% of animals and had a greater antitumor effect (27% complete regression, P less than 0.001) than 750 mu Ci of 131I-labeled irrelevant antibody, a dose that would deliver equivalent radiation to normal organs (liver, kidney, and lung).	Iodine-131	302-306	thymus cell antigen 1, theta	Mus musculus	94-101	
3978621-0	1985	Experimental radiotherapy of murine lymphoma with 131I-labeled anti-Thy 1.1 monoclonal antibody.	Iodine-131	50-54	thymus cell antigen 1, theta	Mus musculus	68-75	
3978621-2	1985	To overcome this limitation, we have evaluated the use of 131I-labeled anti-Thy 1.1 antibodies for the therapy of established AKR/J SL2 lymphoma (Thy 1.1+) nodules growing in congeneic AKR/Cu mice (Thy 1.2+).	Iodine-131	58-62	thymus cell antigen 1, theta	Mus musculus	76-83	
3978621-2	1985	To overcome this limitation, we have evaluated the use of 131I-labeled anti-Thy 1.1 antibodies for the therapy of established AKR/J SL2 lymphoma (Thy 1.1+) nodules growing in congeneic AKR/Cu mice (Thy 1.2+).	Iodine-131	58-62	thymus cell antigen 1, theta	Mus musculus	146-153	
3978621-3	1985	In these experiments, 131I-anti-Thy 1.1 antibody specifically localized to a s.c. tumor with a mean of 6.5% of the infused dose per g of tumor at 24 h after infusion.	Iodine-131	22-26	thymus cell antigen 1, theta	Mus musculus	32-39	
3978621-6	1985	The concentrations of 131I-anti-Thy 1.1 in tumor would result in delivery of a mean of 1600 cGy to tumor following infusion of 500 muCi of 131I-labeled anti-Thy 1.1 antibody.	Iodine-131	22-26	thymus cell antigen 1, theta	Mus musculus	32-39	
3978621-6	1985	The concentrations of 131I-anti-Thy 1.1 in tumor would result in delivery of a mean of 1600 cGy to tumor following infusion of 500 muCi of 131I-labeled anti-Thy 1.1 antibody.	Iodine-131	22-26	thymus cell antigen 1, theta	Mus musculus	157-164	
3978621-6	1985	The concentrations of 131I-anti-Thy 1.1 in tumor would result in delivery of a mean of 1600 cGy to tumor following infusion of 500 muCi of 131I-labeled anti-Thy 1.1 antibody.	Iodine-131	139-143	thymus cell antigen 1, theta	Mus musculus	32-39	
3978621-6	1985	The concentrations of 131I-anti-Thy 1.1 in tumor would result in delivery of a mean of 1600 cGy to tumor following infusion of 500 muCi of 131I-labeled anti-Thy 1.1 antibody.	Iodine-131	139-143	thymus cell antigen 1, theta	Mus musculus	157-164